Efficacy and Safety Study of CD2027 Ointment 3 Microgram Per Gram (mcg/g) Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis
Public ClinicalTrials.gov record NCT00919763. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Four-Week, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CD2027 Ointment 3 mcg/g Twice Daily in the Treatment of Adults With at Least Moderate Atopic Dermatitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This was a multi-center, randomized, double-blind, parallel group study. Efficacy Objectives: To evaluate the efficacy of CD2027 ointment 3 mcg/g applied twice daily over 4 weeks versus its vehicle in adult participants with at least moderate atopic dermatitis. Safety objective: To evaluate safety of CD2027 ointment 3 mcg/g when applied twice daily over 4 weeks versus its vehicle on 5 percent (%) - 20% involved Body Surface Area (BSA) (excluding Head/Neck) in adult participants with at least moderate atopic dermatitis.
Study identification
- NCT ID
- NCT00919763
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 102 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 21, 2009 (Actual)
- Primary completion
- Oct 1, 2009 (Actual)
- Completion
- Oct 1, 2009 (Actual)
- Last update posted
- Jul 19, 2022
2009
United States locations
- U.S. sites
- 14
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Burke Pharmaceutical Research | Hot Springs | Arkansas | 71913 | — |
| Therapeutics Clinical Research, Inc. | San Diego | California | 92123 | — |
| Colorado Medical Research Center, Inc. | Denver | Colorado | 80120 | — |
| Longmont Medical Research Network | Longmont | Colorado | 80501 | — |
| International Dermatology Research, Inc. | Miami | Florida | 33144 | — |
| Dermatology Specialists PSC | Louisville | Kentucky | 40202 | — |
| Minnesota Clinical Study Center | Fridley | Minnesota | 55432 | — |
| Academic Dermatology Associates | Albuquerque | New Mexico | 87106 | — |
| Helendale Dermatology & Medical Spa, LLC | Rochester | New York | 104609 | — |
| Oregon Dermatology & Research Center | Portland | Oregon | 97210 | — |
| Oregon Medical Research Center | Portland | Oregon | 97223 | — |
| Arlington Research Center, Inc. | Arlington | Texas | 76011 | — |
| DermResearch Inc. | Austin | Texas | 78759 | — |
| J&S Studies, Inc. | College Station | Texas | 77845 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00919763, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 19, 2022 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00919763 live on ClinicalTrials.gov.